SCARPA quality assurance Men's Rush Mid GTX Waterproof Shoes a for Hiking Gore-Tex Clothing, Shoes Jewelry , Men , Shoes,Men's,SCARPA,Waterproof,/moorstone659275.html,Hiking,www.w2r-jp.com,Mid,for,Gore-Tex,a,GTX,Rush,Shoes,$125 $125 SCARPA Men's Rush Mid GTX Waterproof Gore-Tex Shoes for Hiking a Clothing, Shoes Jewelry Men Shoes SCARPA quality assurance Men's Rush Mid GTX Waterproof Shoes a for Hiking Gore-Tex Clothing, Shoes Jewelry , Men , Shoes,Men's,SCARPA,Waterproof,/moorstone659275.html,Hiking,www.w2r-jp.com,Mid,for,Gore-Tex,a,GTX,Rush,Shoes,$125 $125 SCARPA Men's Rush Mid GTX Waterproof Gore-Tex Shoes for Hiking a Clothing, Shoes Jewelry Men Shoes

SCARPA Max 66% OFF quality assurance Men's Rush Mid GTX Waterproof Shoes a for Hiking Gore-Tex

SCARPA Men's Rush Mid GTX Waterproof Gore-Tex Shoes for Hiking a

$125

SCARPA Men's Rush Mid GTX Waterproof Gore-Tex Shoes for Hiking a

|||

Product Description

MainMain
Call-outsCall-outs
CraftCraft
Rush Mid GTX Kinesis Pro GTX Rush GTX Moraine Mid GTX Zen Pro
Rush Mid GTX Maverick Mid GTX Rush GTX Moraine Mid GTX Zen Pro
Outsole PRESA Free-dome IKS / SuperGum SCARPA Crossover / SuperGum PRESA Free-dome IKS / SuperGum Vibram Dynatech 3 / XS Trek Vibram Spyder II / TC4+
Midsole 3D EVA CM 3D EVA CM 3D EVA CM (8 mm drop) 2D EVA-CM EVA-I
Upper Fabric amp; Welded PU Synthetic Leather amp; Polyester Mesh Mesh / PU Film / Micro Nubuck 1.8 mm Suede amp; Polyester Mesh 1.8 mm Suede amp; S Tech Fabric
Weight 13.4 oz (1/2 pair, size 42) 1 lb 0.8 oz (1/2 pair, size 42) 13.1 oz (1/2 pair, size 42) 1 lb 2.3 oz (1/2 pair, size 42) 1 lb 1 oz (1/2 pair, size 42)
Height Mid Mid Low Mid Low
Best Use Light Hiking Hiking, Light Backpacking Trail Running, Light Hiking Hiking, Light Backpacking Hiking, Approach
Waterproofing GORE-TEX Extended Comfort GORE-TEX Extended Comfort N/A GORE-TEX Extended Comfort N/A
MSRP 179 169 139 169 179

SCARPA Men's Rush Mid GTX Waterproof Gore-Tex Shoes for Hiking a

CURRENT ISSUE
November, 2021

No. 106 (11)

2020 Impact Factor: 9.941 Submission > Acceptance: 52 days
ARTICLES IN THREE SENTENCES
Article

Transducin β-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma

Transducin β-like protein 1 (TBL1) plays a crucial role in controlling the stability of regulatory proteins involved in cell proliferation and autophagy induction. This study revealed that, unlike normal B cells, diffuse large B-cell lymphoma cells express abundant levels of TBL1 and its overexpression correlates with poor clinical outcome. Targeting TBL1 promoted lymphoma cell death in vitro and in vivo. These results provide the rationale for targeting TBL1 as a novel therapeutic strategy in diffuse large B-cell lymphoma.

Youssef Youssef et al.

Article

Targeting shear gradient activated von Willebrand factor by the novel single-chain antibody A1 reduces occlusive thrombus formation in vitro

The authors of this study developed a single-chain antibody that targets a shear gradient-specific conformation of von Willebrnad factor (VWF). In vitro studies showed that this antibody specifically reduces VWF-GPIbα binding and thrombus formation at sites of shear rate gradients but does not block platelet deposition and aggregation under constant shear rate. This characteristic places the antibody in a new class of antiplatelet therapy for selective blockade of pathological thrombus formation while maintaining normal hemostasis.

Thomas Hoefer et al.

Case Report

Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia

A 26-year-old female developed vaccine-induced immune thrombotic thrombocytopenia (VITT) with cerebral venous thrombosis and bi-hemispheric hemorrhage following the first dose of the ChAdOx1 nCoV-19 vaccine. The treatment protocol, based on intravenous immunoglobulins, dexamethasone and argatroban was successful with almost complete clinical, laboratory and radiological response. This experience supports the application of an early and multidisciplinary therapeutic approach in cases of VITT, with the possibility of avoiding deaths and obtain a resolution of the syndrome.

Sara Bonato et al.

Letter

Allogeneic hematopoietic stem cell transplantation from non-sibling 10/10 HLA-matched related donors: a single-center experience

This retrospective study compared the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) in 23 patients with hematologic malignancies transplanted from non-sibling fully matched related donors to that of patients who underwent conventional haplo-HSCT. Subjects transplanted from fully matched related donors showed trends to a higher relapse rate and lower cumulative incidence of grade II-IV acute graft-versus-host disease, but overall survival was similar. The authors concluded that individualized adjustment of the immunosuppressive treatment is reasonable for this category of patients.

Yaoyao Shen et al.

TAKE ADVANTAGE FROM HAEMATOLOGICA